Search Results - steven+rosenberg

24 Results Sort By:
HLA-class II-restricted T Cell Receptors for PIK3CA “Hotspot” Mutations, E545K and N345K
Summary: The National Cancer Institute (NCI) seeks co-development partners and/or licensees for a collection of T cell receptors (TCRs) that specifically target PIK3CA mutations to treat patients with tumors expressing these mutations in the context of HLA-DPA1*01:03:01, HLA-DPB1*04:01:01 or HLA-DRB1*04:01. Description of Technology: Phosphatidylinositol-4,5-biphosphate...
Published: 11/10/2024   |   Inventor(s): Steven Rosenberg, NIkolaos Zacharakis, S M Rafiqul Islam, Samantha Seitter, Maria Parkhurst, Frank Lowery
Keywords(s):  
Category(s): TherapeuticArea, TherapeuticArea > Oncology, TherapeuticArea > Immunology, Collaboration Sought > Collaboration, Application > Therapeutics
Chimeric Antigen Receptors that Recognize Mesothelin for Cancer Immunotherapy
Abstract: Chimeric antigen receptors (CARs) with high affinity for mesothelin that can be used as an immunotherapy to treat cancers that express mesothelin, such as pancreatic cancer, ovarian cancer, and mesothelioma. The technology includes CAR constructs with one of three different mesothelin-specific antibody portions, including either the mouse-derived...
Published: 4/8/2024   |   Inventor(s): Steven Feldman, Steven Rosenberg, Ira Pastan
Keywords(s): CAR, Immunotherapy, MESOTHELIN, T-CELLS
Category(s): TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics
T Cell Receptors Targeting CDKN2A Mutations for Cancer Immunotherapy
Abstract: Cyclin-dependent kinase inhibitor 2A gene, also known as CDKN2A, is a tumor suppressor gene and is commonly inactivated through somatic mutations in many human cancers. For example, inactivation of CDKN2A is highly prevalent in melanoma, gastrointestinal and pancreatic cancers. Through germline mutations, CDKN2A is associated with predisposition...
Published: 11/6/2024   |   Inventor(s): Sri Krishna, Shoshana Levi, Paul Robbins, Steven Rosenberg, Shirley Nah, Rami Yoseph, Frank Lowery
Keywords(s): adoptive cell therapy, CDKN2A, cyclin dependent kinase inhibitor 2A, Immunotherapy, Krishna, MELANOMA, Neoantigen, Rosenberg, T Cell Receptor, TCR
Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Collaboration
Human T Cell Receptors for Treating Cancer
Abstract: T cell receptors (TCRs) are proteins that recognize antigens in the context of infected or transformed cells and activate T cells to mediate an immune response and destroy abnormal cells. TCRs consist of two domains, one variable domain that recognizes the antigen and one constant region that helps the TCR anchor to the membrane and transmit...
Published: 4/8/2024   |   Inventor(s): Richard Morgan, Nachimuthu Chinnasamy, Steven Rosenberg
Keywords(s): COLON CANCER, Hepatocellular cancer, MELANOMA, PROSTATE CANCER, SSX
Category(s): TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics
Extremely Rapid Method to Isolate Neoantigen Reactive T Cell Receptors (TCRs)
Abstract: Adoptive cell transfer (ACT) uses tumor infiltrating lymphocytes (TILs) that recognize unique antigens expressed by cancer cells (“neoantigens”). Neoantigen specific TIL administration in patients has resulted in long term regression of certain metastatic cancers. However, one of the challenges of ACT and engineered T cell receptor (TCR) therapies...
Published: 4/8/2024   |   Inventor(s): Sri Krishna, Paul Robbins, Rami Yoseph, James Yang, Kenichi Hanada, Frank Lowery, Steven Rosenberg
Keywords(s): act, Adoptive Cell Transfer, Immunotherapy, Neoantigen, Rosenberg, T Cell Receptor, TCR, TIL, tumor, Tumor Infiltrating Lymphocyte
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology
T Cell Receptors Targeting p53 Mutations for Cancer Immunotherapy and Adoptive Cell Therapy
Abstract: The tumor protein p53 is a cell cycle regulator. It responds to DNA damage by triggering the DNA repair pathway and allowing cell division to occur or inducing cell growth arrest, cellular senescence, and/or apoptosis. p53 therefore acts as a tumor suppressor by preventing uncontrolled cell division. However, mutations in p53 that impair...
Published: 4/8/2024   |   Inventor(s): Drew Deniger, Parisa Malekzadeh, Winifred Lo, Rami Yoseph, Paul Robbins, Maria Parkhurst, Anna Pasetto, Yong-Chen Lu, Steven Rosenberg
Keywords(s): Immunotherapy, p53, Rosenberg, T Cell Receptor, TCR, Tumor Protein P53
Category(s): Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, TherapeuticArea > Oncology
A Dendritic Cell Vaccine to Immunize Cancer Patients Against Mutated Neoantigens Expressed by the Autologous Cancer
Abstract: Vaccines against non-viral cancers target mainly differentiation antigens, cancer testis antigens, and overexpressed antigens.  One common feature to these antigens is their presence in central immunological tolerance. Using these vaccines, T cells underwent depletion of high avidity clones directed against such antigens. This depletion can...
Published: 4/8/2024   |   Inventor(s): Gal Cafri, Paul Robbins, Jared Gartner, Steven Rosenberg
Keywords(s): CANCER, Dendritic cells, Immunotherapy, Neoantigens, Rosenberg, T Cells, vaccines
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Vaccines
Neoantigen T Cell Therapy with Neoantigen Vaccination as a Combination Immunotherapy Against Cancer
Abstract: Adoptive cell therapy (ACT) is a breakthrough form of cancer immunotherapy that utilizes autologous, antitumor T cells to attack tumors through recognition of tumor-specific mutations, or neoantigens. A major hurdle in the development of ACT is the exhausted phenotype exhibited by many neoantigen-specific T cells, which limits their efficacy...
Published: 4/8/2024   |   Inventor(s): Sri Krishna, Zhiya Yu, Kenichi Hanada, Steven Rosenberg
Keywords(s): act, Adoptive Cell Transfer, Immunotherapy, Krishna, Neoantigen, Rosenberg, T-Cell Receptor, TCR, Vaccine
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics
T Cell Receptors Targeting KRAS Mutants for Cancer Immunotherapy/Adoptive Cell Therapy
Abstract: Mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS) gene are among the most common oncogenic drivers in human cancers, affecting nearly a third of all solid tumors. Point mutations in the KRAS gene most frequently affect amino acid position 12, resulting in the substitution of the native glycine (G) residue for other amino...
Published: 4/8/2024   |   Inventor(s): Eric Tran, Yong-Chen Lu, Paul Robbins, Steven Rosenberg, Anna Pasetto, Zhili Zheng
Keywords(s): CANCER, Immunotherapy, Mutated KRAS, Rosenberg, T-cell Receptors
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics
T-Cell Therapy Against Patient-Specific Cancer Mutations
Abstract: Human cancers contain genetic mutations that are unique to each patient. Some of the mutated peptides are immunogenic, can be recognized by T cells, and therefore, may serve as therapeutic targets. Scientists at the National Cancer Institute's Surgery Branch developed a method to identify T cells that specifically recognize immunogenic mutations...
Published: 4/8/2024   |   Inventor(s): Eric Tran, Yong-Chen Lu, Paul Robbins, Steven Rosenberg
Keywords(s): Cholangiocarcinoma, Immunogenic, Rosenberg, T-cell, Tran
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology
1 2 3